Pemetrexed and its emerging role in the treatment of thoracic malignancies (Q35117095)

6 August 2017

1 reference

title

Pemetrexed and its emerging role in the treatment of thoracic malignancies (English)

1 reference

6 August 2017

1

Giorgio V Scagliotti

1 reference

6 August 2017

2

Silvia Novello

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

853-863

1 reference

Analysis of current trends in United States mesothelioma incidence

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Continuing increase in mesothelioma mortality in Britain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Malignant pleural mesothelioma: a problematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Advances in the treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

A prospective study of detorubicin in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Use of chemo-radiotherapy in locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Surprise phase III failure for ZD1839.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.5.853

10.1517/13543784.12.5.853

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference